Genetic causes of human heart failure

Journal of Clinical Investigation

Volumn 115, Issue 3, 2005, Pages 518-526

  Morita, Hiroyuki ^b   Seidman, Jonathan ^b   Seidman, Christine E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DYSTROPHIN; GLYCOPROTEIN; RYANODINE RECEPTOR;

CALCIUM SIGNALING; DISEASE COURSE; GENE MUTATION; HEART FAILURE; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; INCIDENCE; MELAS SYNDROME; MITOCHONDRION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH; TRANSCRIPTION REGULATION;

EID: 14644427123     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24351     Document Type: Review

References (96)

1. American Heart Association. 2004. Heart disease and stroke statistics - 2004 update. American Heart Association. http://www.americanheart.org.
2. Seidman, J.G., and Seidman, C. 2001. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 104:557-567.
3. CardioGenomics. Genomics of cardiovascular development, adaptation, and remodeling. NHLBI program for genomic applications. Harvard Medical School. http://cardiogenomics.med.harvard.edu.
4. Morita, H., et al. 2002. Molecular epidemiology of hypertrophic cardiomyopathy. Cold Spring Harb. Symp. Quant. Biol. 67:383-388.
5. Richard, P., et al. 2003. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 107:2227-2232.
6. Watkins, H., et al. 1995. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 332:1058-1064.
7. Moolman, J.C., et al. 1997. Sudden death due to troponin T mutations. J. Am. Coll. Cardiol. 29:549-555.
8. Anan, R., et al. 1994. Prognostic implications of novel β cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J. Clin. Invest. 93:280-285.
9. Fujino, N., et al. 2002. A novel mutation Lys273Glu in the cardiac troponin T gene shows high degree of penetrance and transition from hypertrophic to dilated cardiomyopathy. Am. J. Cardiol. 89:29-33.
10. Kokado, H., et al. 2000. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation. 102:663-669.
11. Regitz-Zagrosek, V., Erdmann, J., Wellnhofer, E., Raible, J., and Fleck, E. 2000. Novel mutation in the alpha-tropomyosin gene and transition from hypertrophic to hypocontractile dilated cardiomyopathy. Circulation. 102:E112-E116.
12. Tyska, M.J., et al. 2000. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ. Res. 86:737-744.
13. Palmer, B.M., et al. 2004. Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. Am. J. Physiol. Heart Circ. Physiol. 287:H91-H99.
14. Palmer, B.M., et al. 2004. Effect of cardiac myosin binding protein-C on mechanoenergetics in mouse myocardium. Circ. Res. 94:1615-1622.
15. Harris, S.P., et al. 2002. Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ. Res. 90:594-601.
16. Geisterfer-Lowrance, A.A., et al. 1996. A mouse model of familial hypertrophic cardiomyopathy. Science. 272:731-734.
17. Carrier, L., et al. 2004. Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc. Res. 63:293-304.
18. Oberst, L., et al. 1998. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J. Clin. Invest. 102:1498-1505.
19. Fatkin, D., et al. 1999. Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the α cardiac myosin heavy chain gene. J. Clin. Invest. 103:147-153.
20. McConnell, B.K., et al. 1999. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J. Clin. Invest. 104:1235-1244.
21. Nishi, H., et al. 1994. Possible gene dose effect of a mutant cardiac beta-myosin heavy chain gene on the clinical expression of familial hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 200:549-556.
22. Ho, C.Y., et al. 2000. Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy. Circulation. 102:1950-1955.
23. Kamisago, M., et al. 2000. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N. Engl. J. Med. 343:1688-1696.
24. Murphy, R.T., et al. 2004. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet. 363:371-372.
25. Olson, T.M., Kishimoto, N.Y., Whitby, F.G., and Michels, V.V. 2001. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J. Mol. Cell. Cardiol. 33:723-732.
26. Olson, T.M., Michels, V.V., Thibodeau, S.N., Tai, Y.S., and Keating, M.T. 1998. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science. 280:750-752.
27. Gerull, B., et al. 2002. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat. Genet. 30:201-204.
28. Itoh-Satoh, M., et al. 2002. Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 291:385-393.
29. Milner, D.J., Weitzer, G., Tran, D., Bradley, A., and Capetanaki, Y. 1996. Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J. Cell Biol. 134:1255-1270.
30. Franz, W.M., et al. 2000. Association of nonsense mutation of dystrophin gene with disruption of sarcoglycan complex in X-Linked dilated cardiomyopathy. Lancet. 355:1781-1785.
31. Badorff, C., et al. 1999. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat. Med. 5:320-326.
32. Sanbe, A., et al. 2004. Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc. Natl. Acad. Sci U. S. A. 101:10132-10136.
33. Wheeler, M.T., et al. 2004. Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J. Clin. Invest. 113:668-675. doi:10.1172/JCI200420410.
34. Olson, T.M., et al. 2002. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation. 105:431-437.
35. Knoll, R., et al. 2002. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell. 111:943-955.
36. Vatta, M., et al. 2003. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J. Am. Coll. Cardiol. 42:2014-2027.
37. Geier, C, et al. 2003. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation. 107:1390-1395.
38. Hayashi, T., et al. 2004. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J. Am. Coll. Cardiol. 44:2192-2201.
39. Arber, S., et al. 1997. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 88:393-403.
40. Nikolova, V., et al. 2004. Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J. Clin. Invest. 113:357-369. doi:10.1172/JCI200419448.
41. Lammerding, J., et al. 2004. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J. Clin. Invest. 113:370-378. doi:10.1172/JCI200419670.
42. McKenna, W.J., et al. 1994. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Br. Heart J. 71:215-218.
43. McKoy, G., et al. 2000. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 355:2119-2124.
44. Norgett, E.E., et al. 2000. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum. Mol. Genet. 9:2761-2766.
45. Rampazzo, A., et al. 2002. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am. J. Hum. Genet. 71:1200-1206.
46. Gerull, B., et al. 2004. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat. Genet. 36:1162-1164.
47. Tiso, N., et al. 2001. Identification of mutations in rhe cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum. Mol. Genet. 10:189-194.
48. Anan, R., et al. 1995. Cardiac involvement in mitochondria! diseases. A study on 17 patients with documented mitochondrial DNA defects. Circulation. 91:955-961.
49. Santorelli, F.M., et al. 1996. Maternally inherited cardiomyopathy and hearing loss associated with a novel mutation in the mitochondrial tRNA(Lys) gene (G8363A). Am. J. Hum. Genet. 58:933-939.
50. Santorelli, F.M., et al. 1999. Maternally inherited cardiomyopathy: an atypical presentation of the mtDNA 12S rRNA gene A1555G mutation. Am. J. Hum. Genet. 64:295-300.
51. Arbustini, E., et al. 1998. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am. J. Pathol. 153:1501-1510.
52. Arad, M., Seidman, J.G., and Seidman, C.E. 2002. Phenotypic diversity in hypertrophic cardiomyopathy. Hum. Mol. Genet. 11:2499-2506.
53. Kemp, B.E., et al. 2003. AMP-activated protein kinase, super metabolic regulator. Biochem. Soc. Trans. 31:162-168.
54. Tian, R., Musi, N., D'Agostino, J., Hirshman, M.F., and Goodyear, L.J. 2001. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation. 104:1664-1669.
55. Arad, M., et al. 2003. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation. 107:2850-2856.
56. Henry, C.G., and Lowry, O.H. 1985. Enzymes and metabolites of glycogen metabolism in canine cardiac Purkinje fibers. Am. J. Physiol. 248:H599-H605.
57. Kubler, W., Schomig, A., and Senges, J. 1985. The conduction and cardiac sympathetic systems: metabolic aspects. J. Am. Coll. Cardiol. 5:157B-161B.
58. Gabrielli, F., Aita, M., Arturi, E., and Alcini, E. 1992. A comparative enzyme histochemical study of glucose metabolism in the conduction system of mammalian hearts. Cell. Mol. Biol. 38:449-455.
59. Wehrens, X.H., et al. 2004. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 304:292-296.
60. Laitinen, P.J., et al. 2001. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 103:485-490.
61. Priori, S.G., et al. 2001. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 103:196-200.
62. Lahat, H., et al. 2001. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am. J. Hum. Genet. 69:1378-1384.
63. Postma, A.V., et al. 2002. Absence of calsequesrrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ. Res. 91:e21-e26.
64. Wehrens, X.H., et al. 2003. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 113:829-840.
65. 2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J. Clin. Invest. 106:1351-1359.
66. Semsarian, C., et al. 2002. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J. Clin. Invest. 109:1013-1020. doi:10.1172/JCI200214677.
67. Doi, M., et al. 2002. Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation. 105:1374-1379.
68. Yano, M., et al. 2003. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation. 107:477-484.
69. Schmitt, J.P., et al. 2003. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 299:1410-1413.
70. Haghighi, K., et al. 2003. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111:869-876. doi:10.1172/JCI200317892.
71. Luo, W., et al. 1994. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ. Res. 75:401-409.
72. Minamisawa, S., et al. 1999. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 99:313-322.
73. DeSantiago, J., Maier, L.S., and Bers, D.M. 2004. Phospholamban is required for CaMKII-dependent recovery of Ca transients and SR Ca reuptake during acidosis in cardiac myocytes. J. Mol. Cell. Cardiol. 36:67-74.
74. Periasamy, M., et al. 1999. Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene. J. Biol. Chem. 274:2556-2562.
75. Zingman, L.V., et al. 2002. Kir6.2 is required for adaptation to stress. Proc. Natl. Acad. Sci. U. S. A. 99:13278-13283.
76. Bienengraeber, M., et al. 2004. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat. Genet. 36:382-387.
77. Komuro, I., and Izumo, S. 1993. Csx: a murine homeobox-containing gene specifically expressed in the developing heart. Proc. Natl. Acad. Sci. U. S. A. 90:8145-8149.
78. Lyons, I., et al. 1995. Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene Nkx2-5. Genes Dev. 9:1654-1666.
79. Tanaka, M., Chen, Z., Bartunkova, S., Yamasaki, N., and Izumo, S. 1999. The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. Development. 126:1269-1280.
80. Schott, J.J., et al. 1998. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science. 281:108-111.
81. Kasahara, H., and Benson, D.W. 2004. Biochemical analyses of eight NKX2.5 homeodomain missense mutations causing atrioventricular block and cardiac anomalies. Cardiovasc. Res. 64:40-51.
82. Biben, C., et al. 2000. Cardiac septal and valvular dysmorphogenesis in mice heterozygous for mutations in the homeobox gene Nkx2-5. Circ. Res. 87:888-895.
83. Tanaka, M., et al. 2002. A mouse model of congenital heart disease: cardiac arrhythmias and atrial septal defect caused by haploinsufficiency of the cardiac transcription factor Csx/Nkx2.5. Cold Spring Harb. Symp. Quant. Biol. 67:317-325.
84. Kasahara, H., et al. 2001. Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein. J. Clin. Invest. 108:189-201. doi:10.1172/JCI200112694.
85. Toko, H., et al. 2002. Csx/Nkx2-5 is required for homeostasis and survival of cardiac myocytes in the adult heart. J. Biol. Chem. 277:24735-24743.
86. Molkentin, J.D., et al. 1998. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:215-228.
87. Frey, N., et al. 2004. Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nat. Med. 10:1336-1343.
88. Zhang, C.L., et al. 2002. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 110:479-488.
89. Chen, F., et al. 2002. Hop is an unusual homeobox gene that modulates cardiac development. Cell. 110:713-723.
90. Shin, C.H., et al. 2002. Modulation of cardiac growth and development by HOP, an unusual homeodomain protein. Cell. 110:725-735.
91. Kook, H., et al. 2003. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J. Clin. Invest. 112:863-871. doi:10.1172/JCI200319137.
92. McKinsey, T.A., and Olson, E.N. 2004. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet. 20:206-213.
93. Finck, B.N., et al. 2002. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109:121-130. doi:10.1172/JCI200214080.
94. Asakawa, M., et al. 2002. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 105:1240-1246.
95. Subbarayan, V., et al. 2000. RXRα overexpression in cardiomyocytes causes dilated cardiomyopathy but fails to rescue myocardial hypoplasia in RXRα-null fetuses. J. Clin. Invest. 105:387-394.
96. Dalakas, M.C., et al. 2000. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N. Engl. J. Med. 342:770-780.